Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose adverse facts regarding its business operations and financial guidance during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Financial Performance - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, which led to a stock price drop of $32.21, or 5.8%, closing at $520.93 per share [2]. - On October 17, 2024, Elevance reported third quarter 2024 financial results, missing EPS consensus estimates by 13.7% and lowering its EPS guidance for 2024 by 11.3%, resulting in a further stock price decline of $52.61, or 10.6%, to close at $444.35 per share [3]. Lawsuit Details - The class action complaint alleges that Elevance's management made materially false and misleading statements and failed to disclose significant adverse facts, including the higher costs associated with sicker patients remaining on Medicaid and inadequate reflection of these costs in financial guidance [4]. - Investors who purchased Elevance common stock during the Class Period have until July 11, 2025, to file a lead plaintiff motion in the lawsuit [5].

Core Insights - UnitedHealth Group Incorporated (UNH) shares have dropped 25.4% in the past month, resulting in a year-to-date loss of 40.4%, significantly underperforming both the broader industry and the S&P 500 [1][7] - The company is facing multiple pressures, including rising medical costs, missed earnings and revenue estimates, and a withdrawal of its 2025 financial guidance [4][15] - Investor sentiment is deteriorating, with numerous downward revisions to earnings estimates for 2025 and 2026, despite projected revenue growth [7][8] Financial Performance - UnitedHealth generated $5.5 billion in operating cash flow in the first quarter, a substantial increase from $1.1 billion the previous year, and ended the quarter with $34.3 billion in cash and short-term investments [14] - The Zacks Consensus Estimate for UNH's 2025 EPS has seen 12 downward revisions, projecting a decline of 17.3%, while revenues are expected to increase by 12.9% year over year [7][8] Market Position and Valuation - UNH is trading at a forward P/E of 12.31X, below its five-year median of 19.20X but above the industry average of 11.50X, indicating a mixed valuation perspective [8][10] - Despite appearing attractively priced, regulatory risks, cost pressures, and reputational damage pose significant threats to the company's business model [10][15] Competitive Advantages - UnitedHealth retains competitive advantages through its vertically integrated model, scale, and investments in AI and digital health, which may help navigate long-term industry trends [12] - The company served 50.1 million members as of March 31, 2025, reflecting a 1.9% year-over-year growth, driven by self-funded commercial plans [13] Outlook and Recommendations - The near-term outlook for UnitedHealth is clouded by setbacks, including regulatory probes and leadership changes, which have undermined investor confidence [15][16] - With no clear catalysts for recovery and significant underperformance, it may be prudent for investors to wait for signs of stabilization before re-entering [16]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's handling of Medicaid eligibility during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including administering Medicaid benefits, which were affected by a federal pause on eligibility reviews during COVID-19 [3]. - Following the end of the pause in 2023, states resumed redetermining Medicaid eligibility, which led to significant increases in acuity and utilization among Elevance's Medicaid members [5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to the redetermination process and believed its negotiated rates were adequate [4]. - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, causing a further stock decline of $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors, including over $438 million in 2019 [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its impact on cost trends [4]. - Defendants assured investors that premium rates negotiated with states were sufficient to manage the risk and costs associated with Medicaid patients, which was later revealed to be misleading [4]. - The true impact of the redetermination process led to a significant rise in acuity and utilization of Medicaid members, contrary to Elevance's financial guidance for 2024 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - On October 17, 2024, Elevance reported Q3 2024 financial results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. The EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Company Operations and Allegations - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. - Elevance had previously claimed to be monitoring cost trends and negotiating sufficient rates for Medicaid patients, which was later alleged to be misleading [4]. Group 3: Stock Performance and Financial Impact - Following a statement on July 17, 2024, regarding increased Medicaid utilization, Elevance's stock price fell by $32.21, nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing consensus EPS expectations by $1.33 (13.7%) due to elevated medical costs in its Medicaid business, resulting in a stock decline of $52.61, nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - Elevance Health's shares have decreased by 27% over the past year, significantly underperforming the broader market over the last 1, 3, and 5 years [1]. Group 1 - The stock's underperformance is attributed to various reasons that are not detailed in the provided content [1].

Core Viewpoint - Investors in Elevance Health, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its financial guidance and operational costs [1][3]. Summary by Sections Lawsuit Details - The lawsuit alleges that between April 18, 2024, and October 16, 2024, Elevance Health failed to disclose critical information to investors, including the fact that sicker patients with higher acuity remained on Medicaid after redetermination, leading to increased per-patient costs [3]. - It is claimed that the rise in costs was not adequately reflected in Elevance's rate negotiations with states or in its financial guidance for 2024, resulting in materially misleading statements about the company's business and prospects [3]. Participation Information - Investors who suffered losses in Elevance Health are encouraged to contact the Law Offices of Howard G. Smith before July 11, 2025, to participate in the ongoing lawsuit [2]. - Interested parties can reach out via email, phone, or the law firm's website for more information regarding their legal rights and the class action [4][5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Elevance Health, Inc. due to allegations of false and misleading statements regarding Medicaid cost trends and earnings guidance, which led to significant stock price declines [3][5][6]. Group 1: Allegations and Financial Impact - The complaint alleges that Elevance and its executives violated federal securities laws by making false statements about monitoring cost trends and the adequacy of premium rates for Medicaid patients [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price decline of $32.21 per share, or 5.8% [6]. - On October 17, 2024, Elevance reported third-quarter earnings that missed consensus EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further stock price decline of $52.61 per share, or 10.6% [7][8]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses in Elevance between April 18, 2024, and October 16, 2024, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][3]. - There is a deadline of July 11, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against Elevance [3]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Elevance Health, Inc. is trading at a discount with a forward 12-month P/E ratio of 10.35X, below its five-year median of 13.46X and the industry average of 13.86X, indicating attractive valuation compared to peers [1][2] Group 1: Growth Drivers - Elevance is positioned for sustained growth through strategic initiatives in its commercial and government segments, with commercial memberships growing 4.6% and 1% year-over-year in 2024, and a notable 14.2% increase in its Individual Commercial business in Q1 2025 [4][5] - The company has streamlined its government business by exiting underperforming markets, enhancing efficiency and potential for growth in Medicare Advantage in underpenetrated states [5] - Elevance's Return on Invested Capital stands at 9.94%, significantly above the industry average of 5.79%, showcasing superior capital deployment capabilities [6] Group 2: Shareholder Returns - The company is committed to returning capital to shareholders, having repurchased $880 million worth of shares in Q1 2025, with $8.4 billion remaining under its buyback authorization, and a dividend yield of 1.82%, exceeding the industry average of 1.40% [7] Group 3: Market Performance - Despite broader market challenges, Elevance shares have gained 1.9% year-to-date, outperforming both the industry and the S&P 500, while peers UnitedHealth and Humana have experienced declines [8] Group 4: Financial Estimates - The Zacks Consensus Estimate for Elevance's EPS indicates a 4.2% increase for 2025 and a 13.8% increase for 2026, with revenue estimates suggesting an 11.2% increase for 2025 and a 7.1% increase for 2026 [11] Group 5: Challenges and Risks - Elevance faces challenges including a decline in Medicaid and Medicare Supplement membership, which could lead to overall membership losses and reduced revenues [12] - Rising medical costs are a significant concern, with the benefit expense ratio increasing from 87% in 2023 to an estimated 88.7% in 2025, indicating pressure on earnings [13] - Regulatory uncertainties, particularly related to the Pharmacy Benefit Management industry, pose additional risks for Elevance [14]